Table 2.
Cytotoxicity of 5-FU, sorafenib, DS-PLGA, 5-FU/DS-PLGA and sorafenib/DS-PLGA in HCC cell lines.
| Huh7 | PLC/PRF/5 | ||
|---|---|---|---|
| IC50s | |||
| 5-FU (μM) | 103.26 (6.21) | 122.84 (8.14) | |
| Sorafenib (μM) | 22.88 (1.26) | 30.89 (2.61) | |
| DS-PLGA (nM) + CuCl2 | 30.69 (3.83) | 49.33 (4.11) | |
| DS-PLGA (nM) + CuGlu | 38.6 (5.88) | 35.5 (7.98) | |
| 5-FU (μM)/DS-PLGA (nM) + CuCl2 | 18.74 (1.09)/18.74 (1.09) | 27.56 (1.09)/27.56 (1.09) | |
| Sorafenib (μM)/DS-PLGA (nM) + CuCl2 | 2.21 (0.19)/22.07 (1.88) | 3.08 (0.12)/30.77 (1.17) | |
| CI Values | |||
| 5-FU/DS | IC50 | 0.001 | 0.003 |
| IC75 | 0.001 | 0.003 | |
| IC90 | 0.002 | 0.002 | |
| Sorafenib/DS | IC50 | 0.006 | 0.051 |
| IC75 | 0.010 | 0.094 | |
| IC90 | 0.018 | 0.178 | |
The figures are IC50s and CI values, respectively. The numbers in the parentheses are the SD; n = 3. CI values: 0.9-1.1additive effect; 0.8-0.9slight synergism; 0.6-0.8moderate synergism; 0.4-0.6synergism; 0.2-0.4 strong synergism. Both CuCl2 and CuGlu are 1 μM.